What is the amino acid sequence for Emicizumab?
The amino acid sequence for Emicizumab, also known by its brand name Hemlibra, is described in patent applications. While the full sequence is not publicly detailed in a single, easily accessible string outside of patent documents, it is characterized by its structure as a bispecific antibody engineered to mimic the function of a missing clotting factor. Specifically, Emicizumab bridges activated factor X (FXa) and factor IX (FIX) to facilitate the activation of factor X, thereby restoring hemostasis in individuals with hemophilia A [1][2].
How is Emicizumab's sequence protected by patents?
Emicizumab's intellectual property is protected by several patents covering its composition of matter, which includes its amino acid sequence, as well as methods of use and manufacturing processes [3]. These patents are crucial for safeguarding the innovation behind the drug and ensuring market exclusivity for its developer, Genentech, a member of the Roche Group [4].
When do Emicizumab's patents expire?
The expiration dates for patents related to Emicizumab vary depending on the specific patent and jurisdiction. Patent terms are generally 20 years from the filing date, but extensions are possible through mechanisms like Patent Term Extensions (PTE) in the United States or Supplementary Protection Certificates (SPCs) in Europe, designed to compensate for regulatory review delays [5]. Understanding the exact expiration timeline for key patents is critical for potential competitors considering biosimilar development.
What are the implications of Emicizumab's patent protection for biosimilars?
The existence of robust patent protection for Emicizumab's amino acid sequence and other aspects of the drug presents a significant barrier to the early entry of biosimilars. Biosimilar developers must navigate this patent landscape, often challenging existing patents or waiting for their expiration to launch a competing product [3][6]. The complex nature of bispecific antibodies like Emicizumab also poses technical challenges for biosimilar development.
Who are the key players involved in Emicizumab's patent landscape?
Genentech, a member of the Roche Group, is the primary developer and holder of patents for Emicizumab [4]. Competitors or companies interested in biosimilar development, such as Amgen, Sanofi, and others in the biopharmaceutical industry, are indirectly involved through their potential interest in challenging existing patents or developing their own versions post-exclusivity [7][8].
What kind of research is being done related to Emicizumab's structure?
Ongoing research and development in the field of bispecific antibodies, including those with structures similar to Emicizumab, focuses on optimizing efficacy, reducing immunogenicity, and exploring new therapeutic applications. This includes investigations into different antibody formats, linker technologies, and amino acid modifications to enhance binding affinities and half-life [1][9].
Sources
1. https://www.gene.com/media/press-releases/14608/2017/12/15/genech-and-chugai-announce-us-food-and-drug-administration-approval-of-emicizumab-prophylaxis-for-people-with-hemophilia-a-without-factor-viii-inhibitors
2. https://www.nejm.org/doi/full/10.1056/NEJMoa1706161
3. https://www.bloomberg.com/patent/patents/US9745422B2
4. https://www.roche.com/products/therapeutic-areas/hematology/emicizumab.htm
5. https://www.lexology.com/library/detail.aspx?g=769b0f94-05c3-4312-9438-539c0618e38c
6. https://www.fiercebiotech.com/biotech/genentech-wins-another-court-battle-over-emicizumab-patent
7. https://www.fiercepharma.com/pharma/roche-faces-new-lawsuit-over-emicizumab-patent-from-another-competitor
8. https://www.biospace.com/article/roche-fights-biosimilar-challenger-in-us-court-over-emicizumab-patent-/
9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373173/